Success Metrics

Clinical Success Rate
84.6%

Based on 11 completed trials

Completion Rate
85%(11/13)
Active Trials
0(0%)
Results Posted
55%(6 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_2
3
23%
Ph phase_4
6
46%
Ph phase_3
3
23%
Ph early_phase_1
1
8%

Phase Distribution

1

Early Stage

3

Mid Stage

9

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
6(46.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(11)
Terminated(2)

Detailed Status

Completed11
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
84.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 23 (23.1%)
Phase 33 (23.1%)
Phase 46 (46.2%)

Trials by Status

terminated215%
completed1185%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

NCT00120367
completedphase_4

Bone Health in Aging HIV Infected Women

NCT02815566
terminatedphase_3

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

NCT01620944
completedearly_phase_1

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
completedphase_3

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

NCT00808002
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00120367Phase 2

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Completed
NCT02815566Phase 4

Bone Health in Aging HIV Infected Women

Completed
NCT01620944Phase 3

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Terminated
NCT03197961Early Phase 1

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

Completed
NCT00808002Phase 3

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Completed
NCT01003990Phase 3

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Completed
NCT02149888Phase 4

PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

Completed
NCT01332227Phase 4

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Completed
NCT00677300Phase 4

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Completed
NCT01270802Phase 4

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Completed
NCT01772940Phase 4

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

Completed
NCT00768989Phase 2

Phase IIB Pilot of Atazanavir + Raltegravir

Terminated
NCT00528060Phase 2

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13